Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report

Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report

This case report describes the treatment of a patient diagnosed with de novo stage 4 human epidermal growth factor 2 (HER2)-positive gastric adenocarcinoma with enteroblastic differentiation (GAED), a rare and aggressive form of gastric cancer characterized by a tubulopapillary growth pattern and en...

Full description

Bibliographic Details
Main Author:	Roger Kai-Cheong Ngan
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Life
Subjects:	antibody-drug conjugate case reports gastric cancer immune checkpoint inhibitors trastuzumab
Online Access:	https://www.mdpi.com/2075-1729/13/9/1851

Similar Items

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results
by: Kenji Nakano
Published: (2023-11-01)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
by: Mariona Riudavets, MD, PhD, et al.
Published: (2022-12-01)

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
by: Alice Indini, et al.
Published: (2021-04-01)

Long-Term Complete Response to Trastuzumab Deruxtecan in a Case of Unresectable Gastric Cancer
by: Hiroaki Yamane, et al.
Published: (2024-03-01)

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
by: Caroline Fong, et al.
Published: (2022-08-01)

Fam-trastuzumab deruxtecan-nxki (Enhertu®): A narrative drug review
by: Ryan Varghese, et al.
Published: (2022-01-01)

Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
by: Vladimir I. Evdokimov, et al.
Published: (2023-12-01)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
by: Huifang Lv, et al.
Published: (2023-01-01)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
by: Toshihiko Matsumoto, et al.
Published: (2022-04-01)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
by: Albouzidi Abderrahmane, et al.
Published: (2011-09-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Trastuzumab: More than a Guide in HER2-Positive Cancer Nanomedicine
by: Celia Nieto, et al.
Published: (2020-08-01)

Coexistence of Gastric Adenocarcinoma and Choriocarcinoma: Complete Response to Trastuzumab and Chemotherapy
by: Seyda Gunduz, et al.
Published: (2012-07-01)

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
by: Xinwei Wang, et al.
Published: (2022-07-01)

Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study
by: Ting Deng, et al.
Published: (2023-05-01)

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
by: Tae-Hwan Kim, et al.
Published: (2021-03-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report
by: Benita Wolf, et al.
Published: (2023-11-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
by: Jeffrey V. Leyton
Published: (2020-07-01)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
by: Yun Yang, et al.
Published: (2018-11-01)

Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
by: Jin-Soo Kim, et al.
Published: (2023-09-01)

Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report
by: Chetan V. Vakkalagadda, MD, et al.
Published: (2023-12-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

Clinically significant radiation necrosis following trastuzumab-deruxtecan and brain stereotactic radiosurgery: A case series in breast cancer patients
by: Victoria Wytiaz, et al.
Published: (2023-06-01)

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice
by: Giulia Notini, et al.
Published: (2024-03-01)

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
by: Chiaki Matsui, et al.
Published: (2023-07-01)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
by: Ju Yang, et al.
Published: (2023-04-01)

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient
by: Junyi Wu, et al.
Published: (2022-01-01)

Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
by: Markus Falk, et al.
Published: (2023-01-01)

The Exciting New Field of HER2-Low Breast Cancer Treatment
by: Daniel Eiger, et al.
Published: (2021-03-01)

A remarkable clinical response in advanced gastric cancer treated with trastuzumab plus capecitabine combination chemotherapy: A report of two cases
by: Naohiko Nakamura, et al.
Published: (2019-04-01)

Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level HER-2 expression: a case report
by: Yurou Xing, et al.
Published: (2024-01-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
by: Lang Y, et al.
Published: (2022-12-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)